Patient and disease characteristics
| . | Fludarabine/melphalan/alemtuzumab (n = 78) . | Fludarabine/melphalan/MTX (n = 51) . | P . |
|---|---|---|---|
| Age, y (median, SD) | 44 (10,7) | 47 (11,3) | .94 |
| Previous transplantation | 35 (45%) | 26 (51%) | .49 |
| Sex mismatched | 34 (55.7%) | 18 (35.3%) | .031 |
| Patient CMV+ | 37 (53%) | 27 (81.8%) | |
| Patient CMV− donor CMV+ | 7 (10%) | 3 (9.1%) | .009 |
| Both CMV− | 26 (37%) | 3 (9.1%) | |
| Disease status at transplantation categorized* | |||
| Low risk | 7 (9.1%) | 7 (13.7%) | .25 |
| CR1 | 6 | 2 | |
| CR2 | 1 | 5 | |
| Intermediate risk | 53 (67.5%) | 27 (52.9%) | |
| More than CR2 | 7 | 2 | |
| 1st PR | 44 | 18 | |
| CR1/2 after 3rd line | 2 | ||
| Untreated relapse/SD treatment | 7 | ||
| High risk | 18 (23.4%) | 17 (33.3%) | |
| Refractory/progressive | 15 | 13 | |
| More than 1st PR | 3 | 4 | |
| Disease | |||
| HD | 15 | 10 | .52 |
| CLL | 8 | 7 | |
| MM | 19 | 16 | |
| MCL | 6 | ||
| Low-grade NHL | 11 | 7 | |
| High-grade NHL | 12 | 4 | |
| T-NHL | 2 | 4 | |
| OCLPDs | 7 | 4 | |
| Follow-up (median, SD) | 400 (273) | 253 (200) | .05 |
| . | Fludarabine/melphalan/alemtuzumab (n = 78) . | Fludarabine/melphalan/MTX (n = 51) . | P . |
|---|---|---|---|
| Age, y (median, SD) | 44 (10,7) | 47 (11,3) | .94 |
| Previous transplantation | 35 (45%) | 26 (51%) | .49 |
| Sex mismatched | 34 (55.7%) | 18 (35.3%) | .031 |
| Patient CMV+ | 37 (53%) | 27 (81.8%) | |
| Patient CMV− donor CMV+ | 7 (10%) | 3 (9.1%) | .009 |
| Both CMV− | 26 (37%) | 3 (9.1%) | |
| Disease status at transplantation categorized* | |||
| Low risk | 7 (9.1%) | 7 (13.7%) | .25 |
| CR1 | 6 | 2 | |
| CR2 | 1 | 5 | |
| Intermediate risk | 53 (67.5%) | 27 (52.9%) | |
| More than CR2 | 7 | 2 | |
| 1st PR | 44 | 18 | |
| CR1/2 after 3rd line | 2 | ||
| Untreated relapse/SD treatment | 7 | ||
| High risk | 18 (23.4%) | 17 (33.3%) | |
| Refractory/progressive | 15 | 13 | |
| More than 1st PR | 3 | 4 | |
| Disease | |||
| HD | 15 | 10 | .52 |
| CLL | 8 | 7 | |
| MM | 19 | 16 | |
| MCL | 6 | ||
| Low-grade NHL | 11 | 7 | |
| High-grade NHL | 12 | 4 | |
| T-NHL | 2 | 4 | |
| OCLPDs | 7 | 4 | |
| Follow-up (median, SD) | 400 (273) | 253 (200) | .05 |
Low risk: CR1, CR2; high risk: refractory, progressive, more than 1st PR.
CR1 indicates 1st complete remission; CR2, 2nd complete remission; 1st PR, first partial response; SD, stable disease; HD, Hodgkin disease; CLL, chronic lymphoid leukemia; MM, multiple myeloma; MCL, mantle cell lymphoma; and OCLPDs, other chronic lymphoproliferative disorders, including Waldenstrom (n = 1/1), T-prolymphocytic leukemia (n = 1), low-grade transformed to high-grade HNL (n = 5/1), Richter (n = 0/2).